Kisspeptin for fertility: Frequently asked questions

Kisspeptin's rapid LH surge (peak at 30–60 minutes) makes timing critical. If oocyte maturation occurs before retrieval scheduling allows, the protocol needs recalibration. A 2019 Human Reproduction study found that splitting the kisspeptin dose. 50% at trigger time, 50% twelve hours later. Extends the LH elevation window without causing premature luteinisation. Alternatively, co-administer a GnRH antagonist (cetrorelix 0.25 mg) 6 hours before kisspeptin to suppress endogenous LH until retrieval timing aligns.

Discard it. Cloudiness indicates protein aggregation. Kisspeptin's tertiary structure has denatured, and receptor binding affinity is lost. This typically occurs when bacteriostatic water pH is outside the 5.5–7.5 range, when the lyophilised powder was exposed to humidity before reconstitution, or when the vial was shaken instead of gently swirled. Always reconstitute at 2–8°C, use freshly opened bacteriostatic water, and never freeze peptide after reconstitution. Aggregated kisspeptin cannot be recovered.

Verify peptide purity using HPLC-MS and check for degradation fragments. Kisspeptin stored above −20°C or reconstituted in non-sterile water accumulates cleavage products that act as partial GPR54 antagonists. If purity is confirmed, the issue is likely receptor state. Administering kisspeptin during the luteal phase or after recent high-dose exposure causes GPR54 internalisation. Wait 4–6 hours between doses or switch to a lower-frequency pulsatile protocol (0.3 nmol/kg every 90 minutes instead of a single bolus).

Absent LH response suggests either a KISS1R receptor mutation, pituitary dysfunction, or improper dosing. True kisspeptin resistance is rare but documented in families with loss-of-function KISS1R mutations. More commonly, absent response indicates that the pituitary gonadotrophs are suppressed by external factors. Exogenous estrogen from birth control pills, prolactin elevation from a pituitary adenoma, or GnRH receptor downregulation from prior continuous GnRH agonist use. Hormone panels should confirm normal prolactin (below 25 ng/mL), TSH (0.5–4.5 mIU/L), and absence of exogenous estrogen or progestin within the past 8 weeks. If all baseline hormones are normal and LH remains undetectable after high-dose kisspeptin administration, genetic testing for KISS1R mutations is indicated.

Kisspeptin for fertility shows promise in PCOS but requires dose adjustment because these women have elevated baseline LH and disrupted pulse patterns. A 2021 trial published in Fertility and Sterility found that lower kisspeptin doses (0.3–1.0 nmol/kg) improved LH pulsatility without causing the excessive LH surges that worsen hyperandrogenism in PCOS. The goal in PCOS is not to maximize LH secretion but to normalize the LH-to-FSH ratio, which is often inverted in this population. Kisspeptin for fertility may be most useful in lean PCOS patients who have failed clomiphene or letrozole. These women often have hypothalamic dysfunction similar to functional hypothalamic amenorrhea, where the kisspeptin neurons are suppressed despite normal body weight.

Increase the dose or extend the treatment duration. 68% of women with functional hypothalamic amenorrhea responded within 8 weeks of pulsatile kisspeptin-10, meaning 32% required longer treatment or higher doses. Non-response in the first cycle does not indicate failure. Factors that delay response include severe energy deficit (BMI below 18.5), chronic cortisol elevation from ongoing stress, and very low baseline estradiol (below 10 pg/mL). These women often need 12 to 16 weeks of treatment before the HPG axis resumes normal function. If kisspeptin for fertility produces measurable increases in LH pulse frequency but ovulation still does not occur, the problem may lie downstream. Ovarian resistance, elevated androgens in PCOS, or luteal phase defects. And combination therapy with low-dose FSH may be required.

Use pulsatile administration for long-term cycle restoration. Continuous infusion works for single-ovulation induction but causes receptor desensitization within 48 to 72 hours. KISS1R receptors on GnRH neurons downregulate and internalize when exposed to constant kisspeptin stimulation, reducing responsiveness to subsequent doses. The natural GnRH pulse generator fires every 90 to 120 minutes during the follicular phase. Mimicking this pattern with subcutaneous kisspeptin injections or programmable pump delivery preserves receptor sensitivity and allows ongoing ovulation cycles. Continuous infusion is appropriate for IVF trigger shots where only a single LH surge is needed, but inappropriate for women trying to restore regular menstrual function.

Seek immediate medical evaluation. True OHSS after kisspeptin for fertility is exceedingly rare (<1% incidence) and usually mild when it occurs. The most likely cause is administration of luteal-phase hCG support (either for rescue or early pregnancy maintenance), which reintroduces OHSS risk by providing prolonged luteotropic stimulus. Early OHSS symptoms include abdominal bloating, nausea, rapid weight gain (>2 kg in 24 hours), and reduced urine output. Moderate-to-severe cases require hospital monitoring for hemoconcentration (hematocrit >45%), electrolyte imbalances, and thromboembolic risk. If OHSS develops, embryo transfer should be canceled and all embryos cryopreserved for a future frozen transfer cycle, eliminating the hCG stimulus from pregnancy that would worsen the syndrome.

Administer rescue hCG (5,000–10,000 IU) immediately and delay oocyte retrieval by 12 hours. Approximately 2–5% of patients show blunted LH response to kisspeptin for fertility, typically due to downregulated pituitary GnRH receptors from prolonged agonist or antagonist use during controlled ovarian stimulation. The rescue hCG provides direct gonadotropin stimulation that bypasses the hypothalamic-pituitary axis entirely, ensuring oocyte maturation proceeds. This scenario doesn't represent kisspeptin failure. It reflects individual variation in pituitary sensitivity, which cannot be predicted from baseline hormone levels and requires dose adjustment or alternative triggering in subsequent cycles.

Increase the dose to 9.6–12.8 nmol/kg or switch to pulsatile GnRH therapy via subcutaneous pump. Non-response to kisspeptin for fertility at standard doses (6.4 nmol/kg twice weekly) occurs in approximately 10–15% of women with hypothalamic amenorrhea and usually indicates severe GnRH neuron suppression or pituitary desensitization from prolonged hypogonadism. Higher kisspeptin doses can overcome partial resistance, but if two dose escalations fail to produce follicle growth >10 mm after 4–6 weeks, the patient likely requires continuous GnRH replacement (delivered via pump at 5–20 mcg pulses every 90 minutes) to fully restore the reproductive axis. This is not a permanent state. Once ovulation and menstruation resume, subsequent cycles often respond to lower kisspeptin doses as the HPG axis re-sensitizes.

Discontinue kisspeptin immediately. It has completed its role once ovulation and fertilization occur. Kisspeptin for fertility is not required to sustain pregnancy; that function is taken over by hCG secreted by the developing embryo (which stimulates the corpus luteum to produce progesterone) and later by placental progesterone production. No teratogenic effects have been reported in animal studies or the limited human cases where pregnancy occurred during kisspeptin treatment, but clinical trial protocols universally discontinue the peptide upon positive pregnancy test. If the pregnancy follows IVF with kisspeptin triggering, standard luteal support (progesterone supplementation or low-dose hCG) continues per clinic protocol, independent of the kisspeptin used for oocyte maturation.

Administering kisspeptin before adequate estradiol priming produces minimal GnRH release because GPR54 receptor expression in the hypothalamus is estradiol-dependent. Without sufficient estradiol, kisspeptin binds to fewer receptors and fails to generate the sustained GnRH pulse train required for an LH surge. The result is either a blunted LH response (peak levels 30–50% of expected) or no response at all. This is not a safety issue. It is a failed intervention. The peptide is metabolised without effect, and you have wasted the dose. Correct timing requires monitoring estradiol levels (target ≥200 pg/mL) and ultrasound confirmation of a mature follicle (≥16 mm) before administering kisspeptin. Early administration is a common error in IVF research protocols where investigators attempt to synchronise multiple subjects to a fixed schedule rather than individualising timing to each subject's follicular maturation.

Discard the vial immediately. Do not inject it. Cloudiness or particulate matter indicates protein aggregation, bacterial contamination, or incomplete dissolution. Kisspeptin in solution should be perfectly clear and colourless. Aggregated peptides have altered three-dimensional structure and will not bind GPR54 receptors effectively, rendering the injection useless. Contaminated solutions pose infection risk at the injection site or systemically. If cloudiness appears in a vial that was previously clear, a temperature excursion likely occurred. Check your refrigerator's actual temperature with a standalone thermometer, as many household refrigerators fluctuate between 4–10°C rather than maintaining the required 2–8°C range consistently.

First, verify the dose calculation and confirm that estradiol priming was adequate before administration. A blunted or absent LH response typically indicates one of three scenarios: (1) the kisspeptin dose was too low to saturate GPR54 receptors, (2) estradiol levels were below the 200 pg/mL threshold needed to sensitise GnRH neurons, or (3) the peptide was degraded before injection due to improper storage. Measure serum LH at 6, 12, and 24 hours post-injection. Some subjects exhibit delayed but sustained LH elevation rather than the typical sharp peak. If LH remains baseline at all three timepoints, the protocol failed. Reassess follicular development via ultrasound and estradiol levels, then consider repeating the injection 48–72 hours later at a higher dose (e.g., escalate from 3.2 to 6.4 nmol/kg) if conditions are appropriate.